Bill Details
HR.1349 - 119th Congress
Status
Latest action
2025-02-13 - Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced Date
2025-02-13
Policy Area
Health
Committees
View committees (2)
Cosponsors
7
0
0
AI Summary This summary was generated by AI from the bill text. AI can get information wrong.
This bill would change Medicare rules so that doctors or other providers who give abortion-inducing drugs could be barred from the Medicare program unless they meet a strict set of conditions. To avoid being excluded, the provider would have to be a physician, examine the patient in person, be in the same room when the drug is given or taken, and set up an in-person follow-up visit within 14 days. The bill says any provider who does not meet these requirements could be permanently removed from Medicare participation for this conduct.
- Applies to providers who prescribe, give, dispense, or furnish abortion-inducing drugs after the bill becomes law.
- Requires a real-time, in-person visit and the physician to be physically present with the patient.
- Requires an in-person follow-up appointment within 14 days after the drug is used.
- Makes the exclusion permanent and says some normal exclusion-review rules would not apply in these cases.
Official Summaries
Women’s Protection in Telehealth Act
This bill excludes providers of abortion-inducing drugs from participating in Medicare unless the provider is a physician who physically examines the patient, is physically present when the drug is administered, and schedules an in-person follow-up visit with the patient within 14 days of administering the drug.
Current Full Text
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1349 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 1349
To amend title XI of the Social Security Act to exclude providers of
certain abortion services from participation in the Medicare program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 13, 2025
Mr. Steube (for himself, Ms. Tenney, Mr. Haridopolos, Mr. McGuire, and
Mr. Biggs of Arizona) introduced the following bill; which was referred
to the Committee on Ways and Means, and in addition to the Committee on
Energy and Commerce, for a period to be subsequently determined by the
Speaker, in each case for consideration of such provisions as fall
within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend title XI of the Social Security Act to exclude providers of
certain abortion services from participation in the Medicare program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Women's Protection in Telehealth
Act''.
SEC. 2. EXCLUDING PROVIDERS OF CERTAIN ABORTION SERVICES FROM
PARTICIPATION IN THE MEDICARE PROGRAM.
Section 1128 of the Social Security Act (42 U.S.C. 1320a-7) is
amended--
(1) in subsection (a)--
(A) in the matter preceding paragraph (1), by
inserting ``(or, in the case of individuals and
entities described in paragraph (5), from participation
in the Medicare program under title XVIII)'' after
``(as defined in section 1128B(f))''; and
(B) by inserting after paragraph (4) the following
new paragraph:
``(5) Provision of abortion-inducing drugs.--Any individual
or entity that, on or after the date of the enactment of this
paragraph, prescribes, administers, dispenses, or furnishes an
abortion-inducing drug to a patient, unless such individual or
entity--
``(A) is a physician;
``(B) physically examines the patient;
``(C) is physically present in the same room with
the patient at the time the patient is administered,
takes, or uses (as applicable) such drug; and
``(D) schedules an in-person follow-up visit for
the patient to occur not more than 14 days after the
patient is administered, takes, or uses (as applicable)
such drug.''; and
(2) in subsection (c)(3)--
(A) in subparagraph (A), by striking ``subsection
(b)(12)'' and inserting ``subsection (a)(5) or
(b)(12)'';
(B) in subparagraph (B), by striking ``subparagraph
(G)'' and inserting ``subparagraphs (G) and (H)'';
(C) in subparagraph (G), by inserting ``(other than
under paragraph (5) of such subsection)'' after
``subsection (a)''; and
(D) by adding at the end the following new
subparagraph:
``(H) In the case of an exclusion under subsection (a)(5), the
exclusion shall be permanent.'';
(3) in subsection (d), by adding at the end the following
new paragraph:
``(4) The provisions of this subsection shall not apply in the case
of an exclusion under subsection (a)(5).'';
(4) in subsection (g), by adding at the end the following
new paragraph:
``(4) The provisions of this subsection shall not apply in the case
of an exclusion under subsection (a)(5).''; and
(5) by adding at the end the following new subsection:
``(k) Abortion-Inducing Drug Defined.--
``(1) In general.--For purposes of subsection (a), the term
`abortion-inducing drug' means any medicine, drug, or any other
substance that is prescribed, administered, dispensed, or
furnished with the intent of terminating the clinically
diagnosable pregnancy of a woman and with knowledge that the
termination will with reasonable likelihood cause the death of
the unborn child (including the off-label use of any such
drug).
``(2) Unborn child.--The term `unborn child' has the
meaning given such term in section 1841 of title 18, United
States Code.''.
<all>